Citadel Advisors - CYTOMX THERAPEUTICS INC ownership

CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 99 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of CYTOMX THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$126,505
+34.8%
98,066
+79.8%
0.00%
Q2 2023$93,833
-79.3%
54,554
-81.9%
0.00%
Q1 2023$454,325
-40.9%
300,877
-37.4%
0.00%
Q4 2022$768,509
+726.4%
480,318
+645.2%
0.00%
Q3 2022$93,000
-85.5%
64,459
-81.6%
0.00%
Q2 2022$642,000
+473.2%
350,689
+727.4%
0.00%
Q1 2022$112,000
-77.7%
42,382
-63.5%
0.00%
Q4 2021$503,000
+867.3%
116,070
+1026.9%
0.00%
Q3 2021$52,000
-99.0%
10,300
-98.7%
0.00%
-100.0%
Q2 2021$4,992,000
-33.5%
788,566
-18.8%
0.00%
-50.0%
Q1 2021$7,504,000
+518.6%
970,810
+424.0%
0.00%
Q4 2020$1,213,000
-35.1%
185,266
-34.1%
0.00%
-100.0%
Q3 2020$1,868,000
+229.5%
280,926
+312.7%
0.00%
Q2 2020$567,000
-63.4%
68,065
-66.3%
0.00%
-100.0%
Q1 2020$1,550,000
-57.2%
202,106
-53.6%
0.00%
-50.0%
Q4 2019$3,619,000
+110.9%
435,569
+87.4%
0.00%
+100.0%
Q3 2019$1,716,000
+366.3%
232,475
+578.0%
0.00%
Q1 2019$368,000
-26.5%
34,290
+26.6%
0.00%
Q3 2018$501,000
-2.5%
27,081
+20.5%
0.00%
Q2 2018$514,000
-61.6%
22,479
-52.2%
0.00%
-100.0%
Q1 2018$1,338,000
+178.2%
47,016
+51.5%
0.00%
Q2 2017$481,000
+53.7%
31,043
+71.4%
0.00%
Q1 2017$313,00018,1160.00%
Other shareholders
CYTOMX THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Aquilo Capital Management, LLC 524,763$7,924,0003.84%
Congress Park Capital LLC 123,311$1,862,0002.05%
Perceptive Advisors 2,911,715$43,588,0001.66%
RTW INVESTMENTS, LP 908,586$13,720,0001.28%
HAMILTON LANE ADVISORS LLC 68,753$1,038,0000.91%
HARBOURVEST PARTNERS LLC 79,193$1,196,0000.57%
SPHERA FUNDS MANAGEMENT LTD. 273,151$4,125,0000.46%
Exane Asset Management 50,000$755,000,0000.44%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 622,548$9,400,0000.38%
Cormorant Asset Management, LP 296,712$4,480,0000.36%
View complete list of CYTOMX THERAPEUTICS INC shareholders